The L-DBF vaccine cross protects mice against different Shigella serotypes after prior exposure to the pathogen

Microbiol Spectr. 2023 Dec 12;11(6):e0006223. doi: 10.1128/spectrum.00062-23. Epub 2023 Oct 3.

Abstract

Shigellosis is endemic to low- and middle-income regions of the world where children are especially vulnerable. In many cases, there are pre-existing antibodies in the local population and the effect of prior exposure should be considered in the development and testing of vaccines against Shigella infection. Our study shows that L-DBF-induced immune responses are not adversely affected by prior exposure to this pathogen. Moreover, somewhat different cytokine profiles were observed in the lungs of vaccinated mice not having been exposed to Shigella, suggesting that the immune responses elicited by Shigella infection and L-DBF vaccination follow different pathways.

Keywords: IFN-γ; IL-17; Il-6; IpaB; IpaD; pre-exposure; shigellosis; vaccine.

MeSH terms

  • Animals
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Proteins / genetics
  • Child
  • Dysentery, Bacillary* / prevention & control
  • Humans
  • Mice
  • Serogroup
  • Shigella Vaccines*
  • Shigella*
  • Vaccines*

Substances

  • Antigens, Bacterial
  • Bacterial Proteins
  • Shigella Vaccines
  • Vaccines
  • Antibodies, Bacterial